home / stock / xrtxf / xrtxf news

XRTXF News and Press, XORTX Therapeutics Inc From 01/12/21

Stock Information
Company Name: XORTX Therapeutics Inc
Stock Symbol: XRTXF
Market: OTC
Website: xortx.com
Menu
XRTXF XRTXF Quote XRTXF Short XRTXF News XRTXF Articles XRTXF Message Board
Get XRTXF Alerts

News, Short Squeeze, Breakout and More Instantly...
XRTXF - XORTX Grants Options

CALGARY, Alberta, Jan. 12, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has granted in accord...
XRTXF - XORTX Announces Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Jan. 07, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: XRX; OTCQB: XRTXF), a biopharmaceutical company focu...

XRTXF - XORTX Announces Grant of European Patent

● Patent supporting Autosomal Dominant Polycystic Kidney Disease Granted – XRx-008 Program ● CALGARY, Alberta, Dec. 29, 2020 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical...

XRTXF - XORTX Announces Topline Results from Mount Sinai's COVID-19 Clinical Study

CALGARY, Alberta, Nov. 16, 2020 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce topline results ...
XRTXF - XORTX Participation in Virtual Conferences

CALGARY, Alberta, Oct. 28, 2020 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participatio...

XRTXF - XORTX Receives Positive Feedback from FDA on COVID-19 Related Acute Kidney Injury

CALGARY, Alberta, Oct. 08, 2020 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a clinical stage pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that...

XRTXF - XORTX Highlights New Studies of Acute Kidney Disease Due to COVID-19 Infection

CALGARY, Alberta, Sept. 15, 2020 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, highlights newly published information...
XRTXF - XORTX Files U.S. FDA Pre-IND Meeting Request for XRx-101 (Oxypurinol) COVID-19 Program and Pre-IND Meeting Submission

CALGARY, Alberta, Aug. 31, 2020 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (CSE : XRX) (OTCQB : XRTXF) (FRANKFURT : ANU1) (the “ Company ” or “ XORTX ”) a late clinical stage pharmaceutical development company focused on kidney disease, is pleased to announ...

XRTXF - XORTX Announces Change to Board of Directors

CALGARY, Alberta, Aug. 28, 2020 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (CSE : XRX) (OTCQB : XRTXF) (FRANKFURT : ANU1) (the “Company” or “XORTX”) a late clinical stage pharmaceutical development company focused on kidney disease, is pleased announce that...

XRTXF - XORTX Therapeutics Moves Toward Phase 3 Trials to Help with an "Orphan" Kidney Disease and COVID-19 Kidney Injuries

e Research Corp. ( www.eresearch.com ) published a 33-page initiation equity Research Report on XORTX Therapeutics Inc. (CSE:XRX ; OTC:XRTXF). e Research initiated coverage with a "Speculative Buy" rating and one-year price target of $2.30. XORTX is focused on kidney diseases with the ...
Previous 10 Next 10